Drug Profile
CH 799
Latest Information Update: 18 May 1998
Price :
$50
*
At a glance
- Originator Celltech Group
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Purine nucleoside phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Irritable bowel syndrome; Osteoarthritis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 18 May 1998 Discontinued-Preclinical for Autoimmune disorders in United Kingdom (PO)
- 18 May 1998 Discontinued-Preclinical for Irritable bowel syndrome in United Kingdom (PO)
- 18 May 1998 Discontinued-Preclinical for Osteoarthritis in United Kingdom (PO)